Target Audience

This program has been designed for medical oncologists, radiation oncologists, OB/GYNs, and other medical professionals who treat patients with breast cancer.

Statement of Need

Breast cancer is the second most common cancer and the second highest cause of cancer death of women in the U.S. The incidence of breast cancer in women in the U.S. is 1 in 8 (about 13%). In 2009, it was estimated 192,370 new cases of invasive and 62,280 new cases of non-invasive (in situ) breast cancer were diagnosed. Approximately 40,170 women were expected to die in 2009 from breast cancer, though death rates have been decreasing since 1990 due to treatment advances, earlier detection through screening, and increased awareness.

Approximately 20-30% of women diagnosed with breast cancer will have a family history of breast cancer. It is estimated 5-10% of breast cancers are caused by gene mutations inherited from one’s mother or father, with mutations of the BRCA1 and BRCA2 being the most common. Women with these mutations have up to an 80% risk of developing breast cancer during their lifetime and are often diagnosed before age 50. About 90% of breast cancers are due not to heredity, but to genetic abnormalities that happen as a result of the aging process and life in general.

Significant advances in the prevention, diagnosis and management of breast cancer have been made in recent years based on the clinical application of scientific discoveries. However, breast cancer remains a complex disease affecting millions worldwide. A 2008 article discussed a gap analysis that was conducted to determine which areas of breast cancer research could produce the greatest impact on patients if targeted by researchers and funding bodies. The aims of the analysis were to determine the gaps in breast cancer knowledge that could result in benefits to patients; to encourage breast cancer researchers and funding bodies worldwide to focus their resources on specific research areas in order to achieve a substantive impact for patients; and to make recommendations for priority action.

Gaps were identified in seven areas (genetics of breast cancer; initiation of breast cancer; progression of breast cancer; therapies and targets in breast cancer; disease markers in breast cancer; prevention of breast cancer; and psychosocial aspects of breast cancer). From the analysis it was found the general barriers to progress were lack of financial and practical resources and poor collaboration between disciplines. In addition, critical gaps in each of the seven areas included: (1) genetics (knowledge of genetic changes, their effects and interactions); (2) initiation of breast cancer (how developmental signaling pathways cause ductal elongation and branching at the cellular level and influence stem cell dynamics, and how their disruption initiates tumor formation); (3) progression of breast cancer (deciphering the intracellular and extracellular regulators of early progression, tumor growth, angiogenesis and metastasis); (4) therapies and targets (understanding who develops advanced disease); (5) disease markers (incorporating intelligent trial design into all studies to ensure new treatments are tested in patient groups stratified using biomarkers); (6) prevention (strategies to prevent estrogen-receptor negative tumors and the long-term effects of chemoprevention for estrogen-receptor positive tumors); (7) psychosocial aspects of cancer (the use of appropriate psychosocial interventions, and the personal impact of all stages of the disease among patients from a range of ethnic and demographic backgrounds).

Learning Objectives

At the conclusion of this educational activity, participants should be able to:

Assess risks and benefits of adjuvant therapy in the elderly early stage breast cancer patient

Define personalized therapy for breast cancer

Accreditation Statement

This activity has been planned and implemented in accordance with
the Essential Areas and policies of the Accreditation Council for
Continuing Medical Education through the joint sponsorship of City of
Hope and Carden Jennings Publishing Co., Ltd. City of Hope is
accredited by the ACCME to provide continuing medical education for
physicians.

Credit Designation

City of Hope designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure

The City of Hope adheres to ACCME Essential Areas, Standards for Commercial Support, and Policies regarding industry support of continuing medical education. Disclosure of the commercial relationships of everyone in a position to control content of an educational activity will be made at the activity. Speakers are also required to openly disclose discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations.

The following CME Committee Members/planners have indicated a conflict with the following corporate organizations:

Jean Kagan discloses that she is a stock shareholder with Amgen/Zimmer

Robert Morgan, MD, discloses that he is a stock shareholder with Abbott

Fouad Kandeel discloses that he is a consultant for MicoCHIPS, Inc. and he has other financial or material interest with Medtronic Minimed

Ravi Bhatia, MD, discloses that he is a consultant with Novartis

J. Martin Hogan, MD, discloses that he has other financial or material interest with Johnson & Johnson

Matthew Loscalzo discloses that he is a member of the speakers bureau with Lilly Pharma

Any potential conflicts relative to the previous disclosure have been resolved.

CJP Medical Communications Disclosure

The employees of CJP Medical Communications have no financial relationships to disclose.

Faculty Disclosures

In accordance with the ACCME’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of everyone in a position to control content of an educational activity. A relevant financial relationship is a relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below:

Arti Hurria, MD, discloses she has received research funding from Abraxis and Pfizer, and is a consultant to Amgen and GenenTech

Laura Kruper, MD, does not have any relevant financial disclosures

Thehang Luu, MD, does not have any relevant financial disclosures

Commercial Support

This activity has been developed through independent educational grants received from Pfizer, Ethicon Endosurgery, and Centocor Ortho Biotech.

Method of Participation

There are no fees for participating in this CME activity. To receive credit during the period November 30, 2010 to November 29, 2011, participants must (1) read the learning objectives and disclosure statements, (2) study the educational activity, (3) complete the posttest, and (4) complete the activity evaluation form, including the certificate information section.

The posttest can be accessed at the end of the activity. Please e-mail any questions to jkagan@coh.org.

Medium

The Internet was selected as the instructional format to accommodate the learning preferences of a significant portion of the target audience.

Disclaimer

Carden Jennings Publishing and the City of Hope present this resource for educational purposes only. Participants are expected to use their own expertise and judgment while engaged in the practice of medicine. Please consult full prescribing information for any drugs or procedures discussed within this activity. The views and opinions expressed in these presentations are those of the authors and do not necessarily reflect the views of the co-sponsors, supporter, or publisher. Although great care has been taken in compiling and checking the information given in this publication to ensure accuracy, the authors, City of Hope and Carden Jennings Publishing and their servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this publication, whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.

Disclosure of Unlabeled Uses

This reference may contain discussion of published and/or investigational uses of agents that are not approved by the US Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product, or consult the Physician’s Desk Reference.

Copyright

All rights reserved; for personal use only. No part of this presentation may be translated, reproduced or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.

Software Requirements

The Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser. If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About.

PC Users

If you need to upgrade your Web browser, follow one of the links listed below:

Microsoft Internet Explorer Downloads (Outside Source)

Mozilla Firefox Product Page (Outside Source)

Adobe Flash Player 9 (Outside Source)

Adobe Acrobat Reader (Outside Source)

Macintosh Users

Compatible Web browsers include:

Firefox (Outside Source)

Apple Safari (Outside Source)

Adobe Flash Player 9 (Outside Source)

Adobe Acrobat Reader (Outside Source)

Privacy Policy

Carden Jennings Publishing collects the information provided by the
user. The information is used to provide notification about upcoming
programs and educational information that may be of interest to our
users. The information is not shared with others for commercial
purposes, unless the user has granted prior permission.

Carden
Jennings Publishing may collect standard Web traffic data such as the
time and date of visit. Carden Jennings Publishing uses this
information to administer its Web site. Browsing activity is recorded
to form aggregate and anonymous demographic information, which is used
as described above. Carden Jennings Publishing does not sell or offer
to sell any user data, including registration and billing information,
to any third parties for commercial purposes. Carden Jennings
Publishing does, when required, provide the minimum subset of
information to third parties that are responsible for accreditation and
issuance of certification of CME/CE tests submitted. By participating
in the Web-based activity, you agree that Carden Jennings Publishing
has full permission to provide this minimum subset of information to
third parties as required by law.